12 results
DEF 14C
BGLC
BioNexus Gene Lab Corp
29 Feb 24
Information statement
5:16pm
to us.
We are distributing this Information Statement to our stockholders in satisfaction of any notice requirements we may have under the WBCA
PRE 14C
BGLC
BioNexus Gene Lab Corp
26 Jan 24
Preliminary information
4:05pm
are distributing this Information Statement to our stockholders in full satisfaction of any notice requirements we may have under the WBCA
8-K
EX-1.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
with such requests to the reasonable satisfaction of the Underwriter.
(b) Representations and Warranties. The representations and warranties of the Company … of any of the representations and warranties, or the satisfaction of any of the covenants, closing conditions or other obligations, contained
8-K
EX-99.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
to commence trading on July 20, 2023, under the symbol “BGLC.” The offering is expected to close on or about July 24, 2023, subject to the satisfaction
8-K
EX-4.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
, the availability of which is established to the reasonable satisfaction of the Company, (ii) a Registration Statement relating to the offer and sale
8-K
EX-10.5
9rwar5cft
30 Dec 20
Entry into a Material Definitive Agreement
2:09pm
8-K
1m3hd9
8 Oct 20
Changes in Registrant's Certifying Accountant
11:32am
S-1
EX-5
58pv18mc4o0wm4mz
29 Jan 19
IPO registration
12:00am
- Prev
- 1
- Next